Tom Woiwode

Tom Woiwode, Ph.D., has been associated with Versant since 2002, contributing significantly in both operational and investment roles. He has served as the startup Chief Business Officer for companies like Amira, Synosia, and Flexion, leading them to successful exits, including Flexion's IPO in 2014. Tom also played a key role as Chief Operating Officer of Okairos, culminating in an acquisition by GSK. Since becoming a Managing Director in 2014, he has led numerous investments reaching successful liquidity events, such as the IPOs of Crispr (2016), Audentes (2016), Gritstone (2018), Crinetics (2018), Aligos (2020), Passage (2020), and Tempest (2021). He also facilitated acquisitions for companies like Jecure, Therachon, and Vividion.